Faron Pharmaceuticals Oy (LSE:FARN) Cash Flow for Dividends: £0.00 Mil (TTM As of Dec. 2025)


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.41
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Cash Flow for Dividends?

Faron Pharmaceuticals Oy LSE:FARN 22 Cash Flow for Dividends is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review.

Faron Pharmaceuticals Oy's cash flow for dividends for the six months ended in Dec. 2025 was £0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Faron Pharmaceuticals Oy Cash Flow for Dividends Related Terms

Faron Pharmaceuticals Oy Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Cash Flow for Dividends Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of £0.00 Mil mean?
Faron Pharmaceuticals Oy (LSE:FARN) has a Cash Flow for Dividends of £0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Cash Flow for Dividends too high?
Faron Pharmaceuticals Oy's current Cash Flow for Dividends is £0.00 Mil. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Cash Flow for Dividends compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Cash Flow for Dividends of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Cash Flow for Dividends is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (LSE:FARN) has a current Cash Flow for Dividends of £0.00 Mil. The current Cash Flow for Dividends is £0.00 Mil. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current Cash Flow for Dividends is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41
Price